Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Average Sales Price Reports To Medicare From Rx Manufacturers Due April 30

Executive Summary

Drug manufacturers' first quarter average sales price reports are due to the Centers for Medicare & Medicaid Services April 30

You may also be interested in...



“Average Sales Price” Rule Issued; Definition Mirrors Medicare Rx Law

CMS' definition of "average sales price" for drugs closely follows the language in the Medicare Rx law

“Average Sales Price” Rule Issued; Definition Mirrors Medicare Rx Law

CMS' definition of "average sales price" for drugs closely follows the language in the Medicare Rx law

ASP Calculations Should Exclude Wholesaler Prompt Pay Discounts, BIO Says

Average sales price calculations for Medicare Part B-covered drugs should exclude the standard 2% "prompt pay" discounts manufacturers pay drug wholesalers, the Biotechnology Industry Organization said

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel